Jan 5, 2024
SAN DIEGO, Jan. 5, 2024 /PRNewswire/ -- VR真人彩票 Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen). This collaboration will be the first relating to the development of VR真人彩票's novel molecular residual disease (MRD) assay, a whole-genome sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA听(ctDNA) to better understand the persistence or recurrence of disease following clinical intervention.
In oncology, MRD testing is听increasingly being used听as a prognostic indicator of disease recurrence after treatment by helping clinicians assess the effectiveness of a patient's current course of clinical intervention and guide their decisions about precision therapy. MRD testing for solid tumors shows promise for improving the standard of care where current disease-monitoring tools fall short听in accurately identifying patients' response to treatment.
"This collaboration reflects the value of our unique MRD technology and the promise of VR真人彩票's whole-genome approach in oncology," said Joydeep Goswami, chief strategy and corporate development officer and chief financial officer of VR真人彩票. "Working together with pharma partners like Janssen, we aim to deliver a sensitive, accurate, and easily accessible whole-genome sequencing MRD assay to advance clinical research in oncology."
The VR真人彩票 WGS MRD assay, which is currently in development, will detect ctDNA for MRD assessment in research settings that evaluate samples from patients previously diagnosed with cancer across multiple听solid tumor indications.听In contrast with existing MRD solutions with complex workflows, VR真人彩票 plans to develop a research solution that will provide a cost-effective, highly sensitive, and automated workflow, with the potential to achieve a turnaround time of five to seven days.
VR真人彩票 intends to collaborate with other leaders in pharma to help further develop and expand the utility of its WGS MRD assay.
Use of forward-looking statements
This article may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are challenges inherent in developing, manufacturing, and launching new products and services, and our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About VR真人彩票
VR真人彩票 is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on , , , , , and .
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
David McAlpine
347-327-1336
PR@illumina.com
View original content to download multimedia:
SOURCE VR真人彩票.
